Life Sciences companies are increasingly utilizing the Web to communicate in new and creative ways. A number of companies have developed very inventive, vibrant technologies to improve the user’s experience and to increase interactivity. Although much can be gained from these new approaches, there are risks as well. Recently, the Washington Legal Foundation asked our partner Joe McMenamin to write a brief summary of some of the issues relevant to online pharma marketing. His paper discusses such topics as rich media, direct-to-physician advertising, blogs, chatrooms, third-party posts, links, metatags and other topics, including the effects upon the continued vitality of the learned intermediary role in the Web 2.0 era.
Click here to access a copy of the paper.